Andrea Gardoni

Andrea Gardoni

Auto-generated profile, based on publicly available information

Andrea Gardoni

Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ESElisabetta Sarasso
Elisabetta Sarasso
AGAndrea Gardoni
Andrea Gardoni
NPNoemi Piramide
Noemi Piramide
MVMaria Antonietta Volontè
Maria Antonietta Volontè
ECElisa Canu
Elisa Canu
FAFederica Agosta
Federica Agosta

22 September 2023 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ESElisabetta Sarasso
Elisabetta Sarasso
AGAndrea Gardoni
Andrea Gardoni
LZLucia Zenere
Lucia Zenere
ECElisa Canu
Elisa Canu
SBSilvia Basaia
Silvia Basaia
FAFederica Agosta
Federica Agosta

28 January 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ESElisabetta Sarasso
Elisabetta Sarasso
DEDaniele Emedoli
Daniele Emedoli
AGAndrea Gardoni
Andrea Gardoni
LZLucia Zenere
Lucia Zenere
ECElisa Canu
Elisa Canu
FAFederica Agosta
Federica Agosta

30 April 2026 in Journal of Neurology
Verified
Journal Article
Open access
Marialuisa GandolfiMarialuisa Gandolfi
Marialuisa Gandolfi
ASAngela Sandri
Angela Sandri
MRMichela Russo
Michela Russo
ESElisabetta Sarasso
Elisabetta Sarasso
AGAndrea Gardoni
Andrea Gardoni
MTMichele Tinazzi
Michele Tinazzi
Functional motor disorders (FMDs) represent a frequent and disabling neurological condition. The lack of reliable diagnostic biomarkers and their heterogeneity might affect diagnosis. We identified multimodal biomarkers distinguishing FMDs from healthy controls (HCs) using machine-learning approaches. In this multicenter cross-sectional study, consecutive adults with a clinically established FMDs diagnosis (n = 75, 74.7% female; mean age 44.20 ± 12.92) and age- and sex-matched HCs (n = 75; 58.6% female; 48.42 ± 11.67) were recruited. All participants underwent standardized behavioral, neurophysiological, and brain MRI assessment exploring motor, exteroceptive, and interoceptive domains. A Random Forest (RF) classifier combined with repeated stratified k-fold cross-validation was trained on the collected features. Predictive performance was evaluated using accuracy, sensitivity, specificity, precision, F1-score, and AUC-ROC. SHapley Additive exPlanations interpreted feature importance. The strongest diagnostic biomarkers were lower dual-task effect scores for postural sway area under eyes-closed motor and cognitive conditions, and gait speed during the motor dual-task, followed by increased vDMN and basal ganglia networks functional connectivity, reduced baseline ipsilateral-contralateral R2 blink reflex area, and higher DNIC-to-baseline N2P2 amplitude ratios for the lower limb. The RF classifier achieved robust performance (accuracy 85.0%, sensitivity 83.9%, specificity 86.1%, F1-score 85.7%, AUC-ROC 0.921). Motor, functional neuroimaging, and neurophysiological markers demonstrated diagnostic value in distinguishing FMDs from healthy controls, addressing the current lack of objective tools and supporting more confident and accurate diagnosis of these heterogeneous conditions. Trial registration number NCT06328790. Registered on 26 March 2024.


6 August 2026 in Journal of Neural Transmission
Verified
Journal Article
Open access
Marialuisa GandolfiMarialuisa Gandolfi
Marialuisa Gandolfi
ASAngela Sandri
Angela Sandri
ESElisabetta Sarasso
Elisabetta Sarasso
AGAndrea Gardoni
Andrea Gardoni
MRMichela Russo
Michela Russo
FAFederica Agosta
Federica Agosta
Functional motor disorders (FMD) are common and disabling conditions, but objective biomarker changes following multidisciplinary management remain limited. Our objective was to investigate changes and responsiveness of multimodal biomarkers in individuals with FMD undergoing multidisciplinary management. 34 patients with clinically definite FMD (mean age 42.76 ± 11.01 years; 85.7% female; mean disease duration 0.64 ± 1.52 years) underwent a standardized multimodal assessment at baseline and 3-month follow-up after a multidisciplinary program. The intervention included a 5-day intensive rehabilitation program (2 h/day), followed by a 12-week phase of telemedicine (one session every 2 weeks) and home-based self-management (two sessions/week). Multimodal biomarkers across motor, exteroceptive, interoceptive, and brain function domains were assessed using clinical, neurophysiological, and task-based functional MRI measures. Motor symptoms improved with concurrent gains in depressive symptoms, physical quality of life, and fatigue (all, p < 0.047). Specific improvements were observed in motor performance, including reduced stride time variability during cognitive dual-tasking ( p = 0.018) and enhanced postural stability mainly in the eyes-closed condition (all, p < 0.028), while neurophysiological and nociceptive measures remained unchanged. Patients showed altered baseline brain activity compared with controls; post-intervention changes were observed in motor, cerebellar, and fronto-insular regions ( p < 0.001, uncorrected), without correlations with clinical outcomes. Multidisciplinary management in FMD was associated with improved clinical outcomes and specific motor and neural changes, suggesting domain-specific responsiveness and a potential role for multimodal biomarkers, requiring confirmation in larger controlled studies. Trial Registration number NCT06328790. Registered on 26 March 2024.